An AGM statement from Yourgene Health (YGEN) includes that it “is delivering rapid growth in line with our expectations” and “confident of the growth strategy we have set ourselves to deliver enhanced shareholder value”…
In its dark days as Premaitha (NIPT), this company was dogged by bully boy US giant Illumina which tried to put it out of business with a claim for patent infringement. New boss Lynn Rees not only sorted that out but as part of the deal, entered a partnership with Illumina. Now the bully boys are on our side.
Four Premaitha (NIPT) bods presented and faced the music at the UK Investor City forum last week. I was hard on them with my questions as were other members of the audience. But I think they coped well and the shares are most certainly a BUY. Enjoy the video and remember that the next forum (featuring Sosandar) is on 3 December. We will start taking bookings next week.
I explain why I am only just home from London and thus livid, elaborating on this piece just up on the complete and utter bastards at Hotels.com. In the podcast I cover last night and Premaitha (NIPT) and Falanx (FLX) and also Berkeley Energia (BKY) and Flybe (FLYB). Warning - very bad language alert.
Tom Winnifrith writes: For the second time Premaitha (NIPT) has served up a trading update for the six months to 30 September and thus having heard the news before it is hardly shocking. FFS do its PR folks think we are stupid or what? Answering my own question, the self important, over-paid, halfwitted knobheads probably do.
There are now just the last 5 ( of 120) places left for the next Wray family organised UK Investor evening seminar in central London. So if you want to book a slot do so now HERE. The event kicks off with drinks and canapes from 5.30 with the first talk just after six. It will be a packed evening.
I am looking forward to grilling Premaitha (NIPT) at the Nigel Wray London seminar on 16 October. There are still a few places going and its free – details HERE. Meanwhile we have three pieces of news this week following that rather disappointing placing at 10p two Friday's ago caused by the a’hole behaviour of the toads at FinnCap. Yes this is Tom Winnifrith writing…
Under promise and over deliver is what PR poltroons tell their AIM clients. So you say you are looking to raise x but know you will raise x and a bit and then call it a massive success even if the placing is only at 66% of the share price a week or so earlier.
Some of you will be aware of my whining about market makers and house broker games played out on the trading floor of AIM. I am sure some of you think these are merely conspiracy theories of a blogger and attempted to explain negative share price movements on a particular day. I'm not going to rehash my market maker theory again, instead, lets discuss a the role of a house broker, I guess these creatures are right at the top of the tree, along with bankers, as a breed of creatures we hate because we feel they cannot be trusted, and yet we are effectively held to ransomed because of the duty they perform.
Tom Winnifrith writes and has also discussed this in bearcast HERE: We ordinary shareholders in Premaitha (NIPT) have suffered for many years and shown enormous loyalty. News released well after the market close of a £2.5 million placing at 10p might thus seem like a kick in the teeth by a management treating us with contempt. I am afraid the story is far worse.
I am extending the Premaitha (NIPT) session at the 16th October UK investor event in London to allow an extended Q&A as I want folks to really grill the company. I shall. You can register and please do so HERE but hurry as the event is already 70% booked out! In this podcast I look at what really happened yesterday and why it shows the City in such a dreadful light. I also look at Tesla (TSLA) and Elon Musk where things go from bad to worse and at new US data and UK house prices.
First things first. If you want free booze, canapes, a chance to see me rip Dominic Frisby apart on blockchain and bitcoin and to hear presentations from and quiz Falanx (FLX) and Premaitha (NIPT) then book a seat for 16 October in central London HERE. In today's podcast I look at Premaitha (NIPT), Avanti Communicatiuons (AVN), Cabot Energy (CAB) and the scandal it won't discuss, Greka Drilling (GDL), SpaceandPeople (SAL) and add to Gary's piece on a CEO who should be going straight to jail and not collecting £400 on the way, Brian McMaster of Jangada Mines (JAN).
First things first. If you want free booze, canapes, a chance to see me rip Dominic Frisby apart on blockchain and bitcoin and to hear presentations from and quiz Falanx (FLX) and Premaitha (NIPT) then book a seat for 16 October in central London HERE. In the podcast I look at the madness of Corbyn once more in relation to the Natural rate of Unemployment in a non broken economy. I add to my earlier comments on troughery at Frontera (FRR) HERE by showing it is bankrupt. I cover Concepta (CPT), Fishing Republic (FISH), the Widecells (WDC) scandal and Wolf Minerals (WLFE).
We have only been waiting three years for this and in the end it came as a complete surprise but a very pleasant one at that. At last Premaitha (NIPT) has settled its patent dispute with American bully boy giants Illumina. This bolt from the blue is great news and now means that a rapidly growing and profitable business will be, at last, valued on fundamentals and that will drive a re-rate which appears to be underway already.
I have had one of those days which happen all too often when I think I want to retire. Blame Laurence Smith. All is explained in this podcast. I look at today's news from Premaitha (NIPT) which is certainly a bolt from the blue, comment on the nature of corporate lying, ref Frontera (FRR), cover RM2 (RM2), Optibiotix (OPTI), Sosandar (SOS) and Online Blockchain (DOG).
In today's podcast I discuss the moral bankruptcy of Naz Shah MP and her comments on Non Invasive Pregnancy Tests, yes Premaitha (NIPT). I look at Tesla (TSLA) and the lessons from women's knickers, at Kefi (KEFI), Frontera (FRR) and the credibility test vs Yorkville, Derriston (DERR) and explain to some folks, I fear it is in house BBM Wildes, what a DCF model involves and why it is used, ref RedT (RED)
Engineering and construction company North Midland Construction (NMD) has announced results for the first half of 2018, including emphasising “our focus on margin enhancement (104% ahead of last year) and cash generation (138% ahead of last year) is beginning to show returns and is anticipated to continue going forward”…
Tom Winnifrith was an insider on this one but opted not to participate in the placing after all the grief he got for taking part on the Premaitha (NIPT) placing at 4.5p a couple of months ago. Premaitha shares are now 9.9p and that is what you may wish to consider.
We are getting increasingly used to Premaitha (NIPT) announcing more and more large non-UK distribution agreements. And fear not there will be much more on that front in the weeks and months that lie ahead. It will be a hot summer for Premaitha and for we loyal shareholders. But, for now, there is something a bit different.
The rehabilitation of Premaitha Health (NIPT) continues. The latest news is from India where there is not even a whiff of a patent challenge from Illumina and where our boys have signed a 3-year agreement with one of the most advanced clinical laboratory groups in the country to provide a bespoke, high quality and scaleable NIPT solution.
This podcast is not about Julie but I just pass on a conversation with a PR man for your amusement. Instead I look in detail at Autyns (AUTG), Magnolia Petroleum (MAGP and the end of its dead cat bounce, and three placings and the resultant aftermarkets: Optibiotix (OPTI), Premaitha (NIPT) and Microsaic (MSYS) and what that says about companies that can exclude Primary Bid. Is it really so bad? Finally, Paul, the idiot from Luton, has sent me £20 and 5% of Bearcast listeners have donated to the Woodlarks charity walk but 95% have not! To those who have donated I say thank you. To the rest, I know you can afford a tenner. Please follow Paul the Idiot from Luton and cough up now HERE
I write from the Kouronis taverna in Kambos where, in the middle of a violent thunderstorm, worthy of Byron at Zitsa, it is sheeting it down. I recorded 90 minutes ago in what seemed like a sauna. All is explained in the podcast which covers Air Partner (AIR), Premaitha (NIPT), a fraud on the Mrs, Akers Biosciences (AKR) and Transense Technologies (TRT). Myself and Brokerman Dan have now raised more than £5,000, including gift aid, for our charity walk on July 28. But 96% of Bearcast listeners are yet to chip in, I am sure you can all spare a tenner so please donate NOW HERE. To those who have donated already, thank you.
So far it has been a good day. I look at four shares I own: Optibiotix (OPTI), Falanx (FLX), Premaitha (NIPT) - yes Wildes you are wrong! - and Sosandar (SOS). And I comment on today's Julie Meyer bombshell. Praise be the Lord. I look at Beowulf Mining (BEM) and wider lessons after its placing and then discuss housebuilders in general after Chris Bailey's excellent article HERE. Chris is right, my old friend Malcolm - a sector bull - is wrong and I explain why.
Let's declare an interest first. FIML, a company owned via a Trust by dependents of Tom Winnifrith, took part in the placing at 4.5p but was scaled back so topped up with market purchases at 6.9p.
First of all thanks to so many of you for your kind responses to yesterday's bearcast - I am now in a serious dialogue with the Police and I hope they will catch and prosecute the culprit. In today's podcast I look at the Sunday Times Rich List which is largely fiction, at Audioboom (BOOM), MySquar (MYSQ), Premaitha (NIPT - where we own shares and indeed have bought more - The People's Operator (TPOP) and Telit (TCM)
Premaitha Health (NIPT) has announced an exclusive partner agreement to offer the IONA non-invasive prenatal test across Egypt and a first Egyptian customer…
Premaitha Health (NIPT) has announced that its IONA test has been approved by Brazil's regulatory authority, Agência Nacional de Vigilância Sanitária (ANVISA), for sale as an in vitro diagnostic test.
I start with a look at the portfolios of those who are crowing as they have aced it for months. I have a warning for them. Then I look at my own portfolio, at the issue of short vs longer term performance at the individual stocks at risk reward and at why I am happy. Under discussion: Mark Slater, Neil Woodford, Optibiotix (OPTI), Reach4Entertainment (R4E), Falanx (FLX), Concepta (CPT), Big Sofa (BST), Premaitha (NIPT). I failed to mention Sosandar (SOS) but I am very happy there too. My HMD podcast I refer to is HERE
Updating on Premaitha Health (NIPT) earlier in the week we noted an up to £2.1 million loan facility agreement to fund costs related to the ongoing Illumina litigation and that a Form of Order hearing is scheduled to take place early this week. The shares are currently rising towards 5p on the back of a UK High Court grants right to appeal announcement from the company…
On last month-announced results for its half year ended 30th September 2017, we noted Premaitha Health (NIPT) currently looking at positive pre-litigation cashflows, but that there remained risk of low cash headroom or even a cash shortfall including if further litigation-related costs are required. There’s now a Secured loan facility agreement with Thermo Fisher announcement.
I should start this piece by making clear that I am a fan of Paul Scott. I think his coverage of the small-cap space is excellent, data-driven and based on years of experience. But his investment in Sosandar (SOS) is a punt too far. I’ve been tempted to comment on Sosandar for a while now but Paul’s Bulletin Board moron-esque attempt at justification yesterday has tipped me over the edge.
After the Illumina legal setback for Premaitha (NIPT) we suggested that the cost of that setback was very manageable – a maximum of less than £2 million is what we hear – and that the underlying business is doing very well. That view is reaffirmed by latest news.
This is not the news we Premaitha (NIPT) shareholders wanted and it is clearly bad news. The question is how bad? The UK High Court has upheld three patent claims made by Illumina against Premaitha.
Well it is a bad day on two counts. Fisrt it is the disaster that has hit our village in Greece and its olive harvest, as I explain in a photo article HERE. Then it is events at Premaitha (NIPT), a share we own. I explain why I am not selling. I look at Stanley Gibbons (SGI) and then at FastForward (FFWD) where things really don't stack up and where there are far more questions than answers.
Premaitha (NIPT) has announced that it has been approved for Brazilian Good Manufacturing Practice for the company's IONA test by Brazil's regulatory authority, the Agência Nacional de Vigilância Sanitária. Jolly good news and it strengthens the story, but it is not the elephant in the room is it?
Premaitha Health (NIPT) has announced that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific announced on 14 December 2015 and extended as announced on 23 September 2016. This is good news.
Premaitha (NIPT) has updated investors on its progress in India where it claims now to have representation in 9 of the 15 most populous states with several of the largest nationwide pathology laboratory groups running Yourgene's NIPT workflow in-house.
Premaitha (NIPT) has updated on trading in the year to March 31 2017. Of course, what matters is not historic trading but the future, that is to say the patent challenge by US corporate fascist bully-boys Ilumina. However, some numbers do matter...
The issue with Genoma was flagged up in the interims pre-Christmas. It owes Premaitha (NIPT) £750,000. That debt looks like a bad debt because the Swiss company has - despite its parent company concluding a fundraise - been having financial issues. So Premaitha has gone to court and had Genoma made bankrupt.
I have been greatly distracted not least dealing with this utterly brain dead and vile Cloudtag (CTAG) shareholder who has been spamming me with the most ghastly abuse all day. I look at the Bob Diamond bid for Panmure Gordon (PMR) and what it means for the wider broking/corporate advisory sector. I then turn to Premaitha (NIPT) and the wider issue of the pointlessness of commissioned research. I touch on Management Resource Solutions (MRS) in light of the news earlier HERE but now the way it is really trying to screw shareholders with a 5p placing. There is comment on Jubilee Platinum (JLP). Then it is back to two old favourites: Advanced Oncotherapy (AVO) and Milestone (MSG). Woof Woof.
We have a new share tip out at 2PM today but here is one which has not dazzled yet. We tipped it an an 18p offer, the shares are now 11.75p-12.5p but we hope readers took our advice and averaged down at as low as 7.5p But the stock is now on a roll and is still cheap. You can catch our new hot tip for just £5 HERE but pro tem back to Premaitha (NIPT).
The fragrant Alice Lane, a foxy young brokerette who apparently I once reduced to tears by being so beastly, is this morning disseminating the latest FinnCap note on Premaitha (NIPT) to clients. Since it is bullish I am happy to make it up to Alice by exposing this high quality research to a wider audience, especially since we own more than a few shares. By way of balance i should say that FinnCap is house broker and therefore utterly partial and you can feel free to ignore every word of this report.
We have four more share tips out between now and January 2nd which you can access for just a fiver HERE, but here is one we prepared earlier which is our first share tip of the year.
Earlier Adam and I chatted about Concepta (CPT). In this podcast we cover Optibiotix (OPTI) and Premaitha (NIPT).
Premaitha (NIPT) has announced that its Thai distributor. Geneplus, has formally signed an agreement to offer the Company's IONA test in the Center for Medical Genomics (CMG), Ramathibodi Hospital, Mahidol University, partnering with the Thailand Center of Excellence for Life Sciences.
Hello Share Keepers. There were interesting responses to my piece which followed Uncle Tom’s thoughts on Premaitha (NIPT). And there’s probably a bit more to say on the wider picture of buying shares in companies which are doing things you may be uneasy about for your own personal, moral reasons.
The Government has announced that as of 2018 it will offer free Non Invasive Prenatal Tests (NIPT) for Downs to women deemed to be at high risk - that is those over 38 years old. Right now it costs you £180 to have an NIPT test rather than an invasive one which has a 1% chance of killing your baby.
Hello Share Collectors. There is a Mel Gibson film being praised at the moment. It tells the story of a soldier in the Second World War who refused to kill, yet still went into battle to save his colleagues.
It seems as if the Governor of the Bank of England Mark Carney wants to quit. I list the numerous reasons why this poltroon should be fired at once. Then there is a discussion of the morality of investment decisions prompted by today's article on Premaitha (NIPT), last week's news from Avocet (AVM) and other issues.
The Guardian has reported that as of 2018 the NHS will offer free non invasive tests for Downs to all at risk women. This is great news for AIM listed Premaitha (NIPT) which is a leading provider of such tests. For it there is a clear financial gain but there is an ethical element here which as a shareholder but also a recent father causes me some issues.
Premaitha (NIPT) announced late last week its results for the year to March 31 2016. Given the pace of events here these historic numbers do not mean that much but for the record:
Apologies for the delay in commenting on this RNS which landed on Friday. We wanted to speak to Adam Reynolds and we have now done so. This is just the start of the good news and ahead of results tomorrow Premaitha (NIPT) shares are a buy.
Finncap is joint broker to Premaitha (NIPT) so is clearly biased. We own shed loads of the shares so are we. So feel free to ignore it all but here is FinnCap's pretty detailed initiation of coverage note.
In the third Dragon's Den session at UK Investor Show the Dragons were myself (Tom Winnifrith) Steve Moore and Brian Kinane. The companies pitching were United Cacao (CHOC), Premaitha (NIPT), ECR Minerals (ECR), Forbidden Technology (FBT) and Asiamet Resources (ARS)
In this session Adam Reynolds and I discussed how to value shells and when to invest, issues of management, AIM investment companies and of course Optibiotix (OPTI), New World Oil & Gas (NEW), Frontier (FRI), and Premaitha (NIPT). Enjoy.
Although the twit who handles PR for Premaitha (NIPT) has again contrived to confuse the issue with some garbled press releases this morning there is actually some good news. Fire the idiot PR man and investors could get excited as they discover what is really going on.
This is an utter shambles from AIM-listed Premaitha (NIPT). If you are going to go to the trouble and (shareholders’) expense of putting out an RNS to highlight some paid-for ramping research by Hardman, at least get the bloody RNS right! Tom Winnifrith has already had a furious rant that the company’s Broker, finnCap, should be sacked. Is the same true of the PR genii behind today’s abject efforts?
The shares of Premaitha (NIPT) have been all over the shop since what was a cracking year end trading statement on Monday. The reason is the cackhanded disposal of Rupert Lywood's remaining 17.9% stake. We thought he was locked in following his last dump on 9 March and a statement signed off by broker Finncap. Weasel words. His shares were placed by Finncap at just 6.5p with directors taking some and solid institutions Helium, Henderson and Hargreave Hale taking the rest. The overhang is now gone but boy has it crushed the shares. Without Lywood's "assistance" since last summer we think the shares would be 20p today. But he is now out of the picture.
Tom Winnifrith was an insider which restricted him from explaining why shares in Premaitha (NIPT) have been weak of late. Now you can see. The company's largest shareholder Rupert Lywood is a total 100% prat
I start with Jimmy Savile as I have no apologies for running this yesterday.The BBC enquiry is just another establishment cover up and I explain why. Then it is onto investor denial at Petroceltic (PCI), not at Premaitha (NIPT), but at LGO Energy (LGO). I explain why Volex (VLX) is - and always will be - a shit company. Then I ask Rob Terry and Knob Park to unblock me on twitter as we should all have an online beer and popcorn party late on Sunday when Slater & Gordon (SGH) reports its results. I'll be up to do a special podcast and it will be fun. I hope you'll be joining me and that Rob will unblock me so he can take part too. There is also a brief comment on Nyota (NYO) where the piggery by a useless CEO is about to stop.
The wider market is taking a bath and Premaitha (NIPT) shares are not immune to this now at 14.5p-15p. But there are also a couple of points which are company specific and in that vein we have had a detailed chat with the company on Friday.
Premaitha Health (NIPT) has announced further international expansion of its customer base and updated on UK litigation timing
Premaitha Health (NIPT) has welcomed the UK National Screening Committee recommendation to routinely offer non-invasive prenatal testing on the NHS to high-risk pregnant women, noting “this is the first time that non-invasive prenatal testing will be routinely available to high risk pregnant women on the NHS and sets a precedent that we expect other countries to follow in the near future” and that“Premaitha is uniquely positioned to bring the benefits of non-invasive prenatal testing to the NHS”
Today at the request of my small handful of readers I look at shares in Dechra Pharma (DPH), Frontera Resources (FRR) and Premaitha Health (NIPT) setting share price targets for all three stocks.
Premaitha Health (NIPT) has noted an announcement from Illumina, Inc. of patent infringement suits against Premaitha's customer in Poland and Ariosa Diagnostics, a subsidiary of Roche, and their customer, The Doctors Laboratory, in the UK, while reiterating that it “continues to make a robust defence against earlier claims by Illumina and the board is confident that the IONA test does not infringe the patents as claimed in the earlier cases or in relation to today's announcement”
I start by explaining to Zak Mir what a dead cat bounce actually means. That brings me to Golden Saint Resources (GSR). Then there is a detailed analysis of the worthless POS that is Magnolia Petroleum (MAGP), comment on why Wildes is so wrong on LGO Energy (TOAST), on Sports Direct (SDI), Premaitha (NIPT) and finally on Games Workshop (GAW) and Mysale (MYSL). I also continue pointing out why lunatics like George Ferguson the barking mad Mayor of Bristol, only serve to make retail stocks even more of an avoid.
Ok this was one of my less successful share tips of the year for 2015 but this time it really will come good. That will be the prompt for guffaws of laughter from Wildes, who is currently sitting on a sinking lifeboat from the doomed SS LGO Energy. But he who laughs last...
A reader posted on our comments section: "Ive also just bought into FFWD. Tom why can't you tip this for 2016 instead of repeat tips on OPTI and NIPT?" Hmmm well I am sure that Optiobiotix shares will race ahead ( 100p + within weeks after the next deal is announced) and that Premaitha will announce new contracts and that it is passed the inflexion point of cash breakeven soon and that its shares will head to 30p+. That is why I tip them as buys. You want me to tip shares that will go up ,right? But your wish is my command and so I will also tip FastForward Innovations. But as a sell at 17p.
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at shares in Anglo Asian Mining (AAZ), Fastnet Equity (FAST) and Premaitha Health (NIPT) setting share price targets for all three stocks.
Premaitha Health (NIPT) has announced results for its half year ended 30th September 2015, that “we have a good pipeline of prospects and we are confident that we will continue to build our revenues throughout the forthcoming period” and an up to £5 million loan facility from $17 billion revenue science company Thermo Fisher.
And now it is the shellmeister Adam Reynolds, he of Optibiotix (OPTI), New World Oil & Gas (NEW) and Premaitha (NIPT) fame presenting at Gold & Bears. A full interview by the Sith Lord with Adam is out today and can be read HERE. Enjoy the video.
Premaitha Health (NIPT) has announced Adgenix as its exclusive distributor in France and that Adgenix has already signed up its first laboratory customer - with a “contract for a minimum of three years to supply LaboSud with the IONA test”
Featuring shares in African Potash (AFPO), New World Oil & Gas (NEW), Premaitha (NIPT), Vast Resources (VAST), Westminster Group (WSG), together with some share price targets.
Tomorrow I am off to Jersey for New World Oil & Gas’ (NEW) Annual General Meeting. If all goes to plan, Adam Reynolds and Nick Lee will be elected to the board, while Peter Sztyk will be deservedly kicked off. Although this should prove to be the watershed moment in New World’s transformation, it will not necessarily trigger an immediate rally in the share price. The hard work begins, once the result is known. However, if Reynolds and Lee remain true to form then 2016 could be incredibly exciting year for this company.
Premaitha (NIPT) has announced some pretty stunning results from an independent test of its IONA test published in the Journal of Ultrasound, Obstetrics in Gynecology. Dam, why did we not get ahead of the news and subscribe to that must read publication? It sounds gripping stuff.
A busy day with my daughter beckons. In the evening it is the new James Bond film. But first a lunchtime bootcamp with Uncle Chris (Booker) to put her straight on the Evil Empire, the EU. In the podcast I ask if InternetQ (INTQ) is the new Globo (GBO)? Then I look at Chemring (CHG), Dialight (DIA) - another win for the bears - Afren (AFR) gets a mention as does LGO Energy (LGO), BP (BP.), Union Jack Oil & Gas (UJO) and - just to niggle Wildes - Premaitha (NIPT) whose shares are moving ahead nicely - more to go there!
If you want me to analyse a stock for you just drop me a line at email@example.com - Today I look at shares in Ferrexpo (FXPO), Paragon Entertainment (PEL), Premaitha Health (NIPT), and setting share price targets for all three stocks
Premaitha Health (NIPT) has announced an agreement with the leading distributor of scientific products in Greece (Antisel SA) to provide its IONA test to clinical laboratories in the region and that it has been informed that American company Illumina, Inc. has added a third patent to its suit against it. Buy, sell or hold?
How can I think straight when Corrie live is on tonight? Anyhow, I continue my debate with Paul Scott on Boohoo.com (BOO). He thinks I'm wrong HERE but I suggest a few points he may wish to consider. Then Lucian Miers flags up the curse of Welsh folks called Williams involved with PLCs - David at Avanti Communications (AVN), Jim and Tony at Arian Silver (AGQ) but is David at Tungsten (TUNG) a sheep shagger? And what about Chris Oil? We need to know. I discuss Arian in its own merits plus Europa Oil & Gas (EOG), Mosman Oil & Gas (MSMN) and in detail Premaitha (NIPT).
This was not going to be my tip in the recently published book "The Magnificent 7" which you can download for free HERE. I was set to tip Optibiotix (OPTI) at c40p. Unfortunately for you (but fortunately for me since we own shares in the company) the share price has raced ahead to a 48p offer. I still think that they could head much higher and Zak Mir reckons that Optibiotix shares will be 60p by October. I think, that is what a chartist terms a long term view.
It is all very well to ridicule the Daily Telegraph’s top ten AIM shares to buy to dodge IHT as I did yesterday HERE but could you do any better asks a reader. Possibly not, I don’t really like the AIM Casino but I am always up for a challenge so here goes.
This morning NWOGaction, the shareholder action group for New World Oil & Gas (NEW), announced its support for Adam Reynolds and his team’s bid for election to the board, at the forthcoming AGM. This is an exciting turn of events for New World’s long-suffering shareholders. It promises to set this stricken company on a much more positive path, led by the value creating force behind the recent flyaway successes of Optibiotix (OPTI) and Premaitha Health (NIPT). Reynolds and his experienced team of turnaround specialists have identified a project and new executive management for New World, in the booming Med Tech space. Now all shareholders have to do is vote in favour of this radical change in direction.
Verdes Management (VMP) has since its AIM admission in 2005 been a total dog. Different management teams have run different models and all have ended in failure. The last chump in charge was Dave Breith of Coms (COMS) infamy. But that is all changing. The shares YESTERDAY weere consolidated and relisted following a RTO by React (REAT) - the company's new name as of today. A refinancing was completed at 1.68p. The shares are a buy at up to 2p with a target to sell of 3.3p before the autumn is too well progressed.
The Daily Mail & BBC this weekend ran stories about how the NHS was doing trials which would see all pregnant women getting a non invasive pre-natal test for down's syndrome. The Mail piece sums it up HERE
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at Cap-XX (CPX), Premaitha Health (NIPT), President Energy (PPC)
Today Pharma giant Roche has snapped up a California based form Ariosa which is big in what is termed NIPT. Panmure Gordon, house broker to Premaitha (NIPT) reckons this has a clear read across for its AIM listed client. In a note sent out today it writes: